Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bioiasis AD's Enterprise Value is €9.66 Mil.
Bioiasis AD's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was €-13.75 Mil. Therefore, Bioiasis AD's EV-to-FCF for today is -0.70.
The historical rank and industry rank for Bioiasis AD's EV-to-FCF or its related term are showing as below:
XBUL:BIOA'
s EV-to-FCF Range Over the Past 10 Years
Min: -6273.89 Med: -7.27 Max: 6266.56
Current: -0.7
During the past 13 years, the highest EV-to-FCF of Bioiasis AD was 6266.56. The lowest was -6273.89. And the median was -7.27.
XBUL:BIOA's EV-to-FCF is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 23.68
vs XBUL:BIOA: -0.70
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bioiasis AD's PE Ratio (TTM) for today is calculated as:
Bioiasis AD's share price for today is €8.25.
Bioiasis AD's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.122.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bioiasis AD EV-to-FCF Related Terms
Bioiasis AD EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bioiasis AD's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bioiasis AD's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioiasis AD EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioiasis AD's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bioiasis AD's EV-to-FCF falls into.
Bioiasis AD's current Enterprise Value is €9.66 Mil.
Bioiasis AD's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioiasis AD (XBUL:BIOA) has a EV-to-FCF of -0.70 as of Sep. 10, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioiasis AD and its competitors.
Is Bioiasis AD's EV-to-FCF too high?
Bioiasis AD's current EV-to-FCF is -0.70. Overall, Bioiasis AD has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bioiasis AD's EV-to-FCF compare to ABT and SYK?
Bioiasis AD's EV-to-FCF of -0.70 can be compared against companies in the Medical Devices & Instruments industry. The industry median EV-to-FCF is 23.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.68, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioiasis AD and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioiasis AD's current EV-to-FCF is -0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioiasis AD stock overvalued right now?
Bioiasis AD (XBUL:BIOA) has a current EV-to-FCF of -0.70. The current EV-to-FCF is -0.70. Bioiasis AD's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bioiasis AD (XBUL:BIOA), the current EV-to-FCF is -0.70 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bioiasis AD provides specialized medical devices, equipment, and consultation services to state and private hospitals and trading companies. The company also deals in Interventional Cardiology and General Surgery consumables.
12GF Score
Get the complete analysis for XBUL:BIOA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:BIOA has been successfully added to your 
